SpringWorks Therapeutics Q1 2024 GAAP EPS $(1.18) Misses $(1.16) Estimate, Sales $21.006M Beat $12.206M Estimate
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics (NASDAQ:SWTX) reported Q1 2024 earnings with a GAAP EPS of $(1.18), missing the $(1.16) estimate, and sales of $21.006M, surpassing the $12.206M estimate. The EPS remained unchanged from the previous year, while sales significantly exceeded expectations.
May 02, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
SpringWorks Therapeutics reported a Q1 2024 GAAP EPS of $(1.18), missing estimates, but sales of $21.006M exceeded expectations.
While the EPS miss might concern some investors, the significant beat on sales could indicate stronger than expected revenue growth, potentially offsetting concerns about profitability in the short term. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100